Burrill & Company

Burrill & Company is a diversified global financial services firm focused on the life sciences industry. For more information visit: www.burrillandco.com.

Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking, and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and vi

sibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia.

26/08/2013

Congrats to Burrill & Company portfolio company Ceptaris Therapeutics on winning FDA approval for Valchlor!

MALVERN, PA (August 26, 2013) -- Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for the orphan drug VALCHLOR™ (mechlorethamine) gel for the topical treatment of stage IA…

02/08/2013

So much for the dog days of summer. During July, 6 more biotech companies took a running leap through the wide open IPO window, joining a growing pool of newly-made public companies.

29/07/2013

Join G. Steven Burrill for the very first Digital Health Days forum in Stockholm August 21-22. Learn more or register today: http://www.digitalhealthdays.se/

27/07/2013

Funding for privately held healthcare biotechs up 38.7% in H1 http://bit.ly/15l4NOK

11/07/2013

G. Steven Burrill presents “A Global Look at the Life Sciences Industry," a keynote address at the ASEAN Life Sciences Conference on July 17. Join us or learn more: http://www.asean-lifesciences.org/home

02/07/2013

We're excited about Life Science Innovation Northwest! Will you join us in Seattle July 10-11?

Register today and save!
http://conta.cc/13oFyfZ

01/07/2013

Life Sciences companies raised $56.2 billion in cash during the first half of 2013 -- 60.4 percent more than the $35 billion raised during the same period a year ago -- as companies capitalized on rising share prices, encouraging clinical results, and improving economic prospects

14/05/2013

Around the world, lifespans are increasing and populations are aging. This demographic shift presents opportunities for drug and device developers, as well as significant challenges for healthcare systems and payers. Diseases of aging are among the costliest and most intractable diseases we face. Th...

08/05/2013

How Design of Mobile Apps Can Promote Healthier Behavior - WSJ at the Burrill Digital Health Mtg http://on.wsj.com/15nNjo9

Companies can entice people to health technologies if they woo them into sharing and celebrating, a design guru says.

02/05/2013

Burrill Business Plan Competition fosters student entrepreneurship (April 30, 2013) http://bit.ly/ZWlLTm

Chris Meyer (left), a graduate student in mechanical engineering, describes his company proposal to judges during the 2010 G. Steven Burrill Business Plan Competition.

25/04/2013

Thanks to everyone who joined us at Steve's State of the Industry Super Session at and to BIOtech Now for this nice recap.

To open his Super Session at the 2013 BIO International Convention, G. Steven Burrill, CEO of Burrill & Company, injected some humor for the hundreds of